4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-25-286212
Chief Scientific Officer sold 8,500 shares at an average $25.19 ($214,091)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2025-11-17 | Sale 10b5-1 | −3,156 | $24.84 | $78,395 | 406,486 | D: show line 1 in the form |
| Bredt David Chief Scientific Officer | 2025-11-17 | Sale 10b5-1 | −5,344 | $25.39 | $135,696 | 401,142 | D: show line 2 in the form |
| Open-market sales · 8,500 sh · avg $25.19 · $214,091 | |||||||
Loading xslF345X05/ownership.xml…